Metastasis Companion Diagnostic
Multiple Solid Tumors
Prospective Clinical TrialsOngoing
Key Facts
Indication
Multiple Solid Tumors
Phase
Prospective Clinical Trials
Status
Ongoing
Company
About Mestastop Solutions
Mestastop Solutions develops proprietary platforms to unravel metastasis biology for drug discovery and companion diagnostics in oncology.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Abexinostat + Pembrolizumab | Xynomic Pharmaceuticals | Phase 1b |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| UNO (Ultrahigh NO) | Beyond Air | Phase 1/2 |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| Anti-metastasis Drug Discovery | Mestastop Solutions | Preclinical/Discovery |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |